Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pyxis Oncology (PYXS) EBIT Margin (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed EBIT Margin for 2 consecutive years, with 165.75% as the latest value for Q4 2025.

  • Quarterly EBIT Margin changed N/A to 165.75% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 609.18% through Dec 2025, down 5511.0% year-over-year, with the annual reading at 609.18% for FY2025, 5511.0% down from the prior year.
  • EBIT Margin for Q4 2025 was 165.75% at Pyxis Oncology, up from 700.35% in the prior quarter.
  • The five-year high for EBIT Margin was 34.71% in Q1 2024, with the low at 700.35% in Q2 2025.